eXoZymes Inc. reported significant financial challenges in its latest quarterly filing for the period ending September 30, 2025. The company recorded a net loss of $6.5 million, a 61.6% increase from the $4.0 million loss reported in the same period last year. Total operating costs surged to $7.0 million, up 77.8% from $3.9 million in the prior year, primarily driven by increased research and development expenses and higher general and administrative costs. The company did not generate any operating income during the quarter, maintaining its pre-revenue status.
The financial position of eXoZymes has deteriorated compared to the previous fiscal period, with total assets decreasing by 40.8% to $7.7 million from $13.0 million at the end of 2024. Cash and cash equivalents fell by 47.5% to $5.1 million, reflecting a significant cash burn rate as the company continues to invest heavily in its operations. The decline in grants receivable, which dropped 59% to $302,643, indicates a reduction in funding from government sources, further straining the company's liquidity.
Operationally, eXoZymes has made strategic moves, including the establishment of a new subsidiary, NCTx LLC, focused on developing a rare plant-derived compound relevant to metabolic health. The company also signed a joint venture with Neuractas Therapeutics to explore cannabinoid molecules, although no business activities have occurred to date. The workforce has expanded, contributing to increased compensation expenses, which rose by 51.6% year-over-year. As of September 30, 2025, the company employed a total of 8,387,250 common shares, reflecting a slight increase from the previous year.
Looking ahead, eXoZymes faces substantial challenges in securing additional funding to support its operations and growth initiatives. The company has indicated that its ability to meet long-term obligations depends on obtaining further financial support, either through equity or debt financing. Management remains optimistic about its technology's potential to transform biomanufacturing, but acknowledges the need for continued investment and development to achieve commercial viability. The company is actively pursuing additional grants and funding opportunities to bolster its financial position in the near term.
About EXOZYMES INC.
eXoZymes Inc. develops cell-free biomanufacturing solutions using engineered enzymes called exozymes, enabled by AI and bioengineering. Its platform produces valuable chemicals for nutraceuticals, pharmaceuticals, and biofuels, offering sustainable, scalable alternatives to traditional petrochemical and synthetic biology methods. The company focuses on licensing, partnerships, and spinouts to commercialize its innovative biosolutions in the biomanufacturing industry.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.